Super Micro Computer: Why It's Still Worth Having In Your Portfolio (Archive) SMCI combines robust backlog growth, moderated valuations, and technicals that still favor outperformance.
XPLR Infrastructure: Sell Now If You Haven't Already (Archive) XPLR slashes payouts, pivots to self-funded growth, but remains a bearish transition story.
ASML: Why It's Too Early To Buy (Archive) ASML’s growth hinges on services as weakening system demand and bookings temper upside.
Nvidia: Not Yet A Buy, Here's What To Wait For (Archive) Waiting for a deeper pullback before loading up on Nvidia's next growth leg.
Enovix: A Worthy Buy For Asymmetric Upside (Archive) Enovix offers asymmetric upside as commercialization lags but customer, manufacturing, and R&D milestones advance.
Devon Energy: Stay Away From This Value Trap (Archive) Limited growth, mixed commodity outlook, and murky technicals make DVN a likely value trap.
CVS Health: One Good Quarter Is Not Enough; Retain Sell (Archive) CVS' rally masks persistent insurance margin pressures, rich valuation, and rising leverage risks.